Peripheral Arterial Disease Trial, Recruiting NCT05391815 Sponsor: Shanghai Zhongshan Hospital Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT05391815
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a level of limb blood flow problems rated between grades 3 and 6 on a standard medical scale (this covers moderate to severe symptoms — confirm with trial site)
  • You are able and willing to attend follow-up appointments as scheduled
  • You are between 18 and 80 years old
  • The blocked or narrowed blood vessels being treated are located in the lower part of the main abdominal artery and/or the large arteries in the hip/pelvic area (iliac arteries)
  • The affected blood vessel is at least 50% narrowed, fully blocked, has been previously treated and re-narrowed, or has a blood clot that has already been partially cleared by a procedure
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • You have a known allergy to any medications used in this study, including blood-thinning or anti-clotting drugs
  • You have a known allergy to the dye used in imaging scans (iodine contrast agent)
  • You have a condition that affects how your blood clots, either clotting too little or too much
  • You are currently pregnant or breastfeeding
  • Your life expectancy is estimated to be less than 24 months
  • Your overall health means you are not well enough to safely undergo a minimally invasive (endovascular) procedure
  • You have a specific type of severe limb blood flow problem classified as Type 2B or Type 3 lower limb ischemia (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86021-64041990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2021
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Freedom from clinically-driven TLR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov